
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc shows a promising outlook as the company's Precision Diagnostic products, particularly POSLUMA, are projected to capture a higher market share and revenue growth in PSMA PET imaging, with expectations of a shift from a low-single-digit to a high-single-digit percentage share by 2025. Additionally, the introduction of a new Pylarify formulary is expected to enhance production capacity by approximately 50%, combined with three years of TPT eligibility, which should invigorate growth in this segment starting in late 2026. Furthermore, any potential growth from non-Pylarify segments may significantly exceed current modeling expectations, providing additional momentum for higher earnings per share in 2026 and 2027.
Bears say
Lantheus Holdings Inc has experienced a significant decline in revenue from its Pylarify product, reporting $260 million, which is an 8% year-over-year decrease and approximately $14 million below consensus expectations. Additionally, unit growth fell short at only 2% year-over-year, coupled with a notable price headwind of 10% during the quarter, further exacerbating the company's challenges. With lowered growth forecasts for 2025-2026 and a growth profile that is now trailing behind profitable SMID MedTech peers, Lantheus's long-term financial performance appears to be under strain.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares